company background image

Orphazyme CPSE:ORPHA Stock Report

Last Price


Market Cap







26 May, 2022


Company Financials
ORPHA fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health3/6

ORPHA Stock Overview

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases.

Orphazyme Competitors













Price History & Performance

Summary of all time highs, changes and price drops for Orphazyme
Historical stock prices
Current Share Pricekr.1.29
52 Week Highkr.109.10
52 Week Lowkr.1.10
1 Month Change-53.93%
3 Month Change-84.61%
1 Year Change-96.17%
3 Year Change-97.44%
5 Year Changen/a
Change since IPO-98.39%

Recent News & Updates

Shareholder Returns

ORPHADK BiotechsDK Market

Return vs Industry: ORPHA underperformed the Danish Biotechs industry which returned -17% over the past year.

Return vs Market: ORPHA underperformed the Danish Market which returned 1% over the past year.

Price Volatility

Is ORPHA's price volatile compared to industry and market?
ORPHA volatility
ORPHA Average Weekly Movement21.4%
Biotechs Industry Average Movement8.1%
Market Average Movement6.3%
10% most volatile stocks in DK Market10.7%
10% least volatile stocks in DK Market3.8%

Stable Share Price: ORPHA is more volatile than 90% of Danish stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: ORPHA's weekly volatility has decreased from 27% to 21% over the past year, but is still higher than 75% of Danish stocks.

About the Company

2009180Anders Vadsholt

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease.

Orphazyme Fundamentals Summary

How do Orphazyme's earnings and revenue compare to its market cap?
ORPHA fundamental statistics
Market Capkr.45.55m
Earnings (TTM)-kr.845.61m
Revenue (TTM)kr.13.15m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ORPHA income statement (TTM)
Cost of Revenuekr.0
Gross Profitkr.13.15m
Other Expenseskr.858.76m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Jun 07, 2022

Earnings per share (EPS)-23.95
Gross Margin100.00%
Net Profit Margin-6,429.52%
Debt/Equity Ratio28.1%

How did ORPHA perform over the long term?

See historical performance and comparison


Is Orphazyme undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ORPHA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ORPHA's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: ORPHA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: ORPHA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Danish market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ORPHA's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ORPHA is good value based on its Price-To-Book Ratio (0.3x) compared to the DK Biotechs industry average (5.6x).

Future Growth

How is Orphazyme forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orphazyme has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Orphazyme performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ORPHA is currently unprofitable.

Growing Profit Margin: ORPHA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ORPHA is unprofitable, and losses have increased over the past 5 years at a rate of 49.2% per year.

Accelerating Growth: Unable to compare ORPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORPHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: ORPHA has a negative Return on Equity (-507.08%), as it is currently unprofitable.

Financial Health

How is Orphazyme's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ORPHA's short term assets (DKK403.7M) exceed its short term liabilities (DKK223.7M).

Long Term Liabilities: ORPHA's short term assets (DKK403.7M) exceed its long term liabilities (DKK37.6M).

Debt to Equity History and Analysis

Debt Level: ORPHA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ORPHA's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ORPHA has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ORPHA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


What is Orphazyme current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORPHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORPHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORPHA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORPHA's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ORPHA has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Anders Vadsholt (52 yo)





Mr. Anders Fink Vadsholt, M.Sc., M.B.A., serves Chief Executive Officer since 2022 & Chief Financial Officer since May 2016 of Orphazyme A/S (formerly known as Orphazyme ApS) and served as its Interim Chie...

CEO Compensation Analysis

Compensation vs Market: Anders's total compensation ($USD1.24M) is above average for companies of similar size in the Danish market ($USD410.50K).

Compensation vs Earnings: Anders's compensation has increased whilst the company is unprofitable.

Board Members

Experienced Board: ORPHA's board of directors are considered experienced (5.6 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Orphazyme A/S's employee growth, exchange listings and data sources

Key Information

  • Name: Orphazyme A/S
  • Ticker: ORPHA
  • Exchange: CPSE
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr.45.553m
  • Shares outstanding: 35.31m
  • Website:

Number of Employees


  • Orphazyme A/S
  • Ole Maaløes Vej 3
  • Copenhagen
  • Capital Region of Denmark
  • 2200
  • Denmark


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/26 00:00
End of Day Share Price2022/05/25 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.